These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30593952)

  • 21. Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.
    Kim TH; Suh DH; Kim MK; Song YS
    Biomed Res Int; 2014; 2014():132702. PubMed ID: 25050322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
    Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
    Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
    Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
    Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.
    Tossetta G
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
    Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
    Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
    Tang W; Ren A; Xiao H; Sun H; Li B
    Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.
    Somasagara RR; Tripathi K; Spencer SM; Clark DW; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Piazza GA; Palle K
    Biochem Biophys Res Commun; 2016 Jan; 469(3):449-55. PubMed ID: 26679603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
    Shi L; Xi J; Xu X; Peng B; Zhang B
    Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.
    Cole JM; Joseph S; Sudhahar CG; Cowden Dahl KD
    J Vis Exp; 2014 Sep; (91):51891. PubMed ID: 25285606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
    Hirst J; Pathak HB; Hyter S; Pessetto ZY; Ly T; Graw S; Koestler DC; Krieg AJ; Roby KF; Godwin AK
    Cancer Res; 2018 Aug; 78(15):4370-4385. PubMed ID: 29891506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.
    Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
    Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.